Shuimu Molecule's ChatDD AI drug design platform and its preclinical candidate timeline
Overview
Shuimu Molecule, a three-year-old AI drug company incubated by Tsinghua AIR, says its ChatDD platform lets drug researchers direct AI agents through natural-language dialogue.
The company says a self-developed autoimmune bispecific antibody project reached a preclinical candidate in seven months, compared with 12 to 24 months using traditional methods. QbitAI reports the claims and notes that CCTV named Shuimu the only AI pharmaceutical firm on its "Ten Steeds of China's AI Startups" list.
Written by AI from the articles below · updated Nov 2, 3:24 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- QbitAINewsShuimu Molecule, a Tsinghua AIR spinout, builds conversational AI drug design platform ChatDD
AIShuimu Molecule, a three-year-old AI drug company incubated by Tsinghua AIR, is the only AI pharmaceutical firm on CCTV's "Ten Steeds of China's AI Startups" list. The company's ChatDD platform lets drug researchers direct AI agents through natural-language dialogue, and it says a self-developed autoimmune bispecific antibody project reached preclinical candidate in seven months, versus 12–24 months with traditional methods.
Heat Trend
- Current comparable heat
- 7
- Peak comparable heat
- 9Nov 2, 4:00 AM ET
- Change in past 24 hours
- –
The trend compares only continuously observed participants, so its scope may be smaller than the current heat total. Hover or tap for hourly heat; use arrow keys with a keyboard.